Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...